Biomind arranges $2.52-million private placement

Executive Summary

• Biomind Labs Inc. has announced a non-brokered private placement of up to 28 million units at a price of CAD $0.09 per unit, targeting gross proceeds of up to CAD $2.52 million.
• Each unit consists of one common share and one common share purchase warrant, with warrants exercisable at CAD $0.12 per share for a period of 24 months.
• Net proceeds are designated for advancing clinical development programs, regulatory preparations, and general working capital.

Key Details

• Transaction Structure: Non-brokered private placement.
• Units Offered: Up to 28,000,000 units.
• Price Per Unit: CAD $0.09.
• Gross Proceeds: Up to CAD $2.52 million.
• Warrant Terms: Each unit includes one common share purchase warrant; each warrant allows the holder to acquire one common share at an exercise price of CAD $0.12.
• Warrant Duration: 24 months following the completion of the offering.
• Closing Date: Expected on or about February 6, 2026.
• Hold Period: Securities are subject to a statutory hold period of four months and one day from the date of issuance.
• Use of Proceeds: Advancing clinical development programs, regulatory preparations, and general working capital.
• Finder’s Fees: The company may pay finders' fees to eligible finders in accordance with applicable securities laws and Cboe Canada policies.